Generated by AI
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA. The company is building therapies intended to address diseases caused by defined genetic alterations, with research programs spanning hematology, immunology and oncology, liver, lung, ocular, and neuromuscular conditions. Its current work centers on investigational, pre-commercial product candidates and platform capabilities that support targeted genetic correction across multiple tissues and disease areas. Prime Medicine, Inc. plays a specialized role in the broader genetic medicines market by advancing next-generation editing approaches aimed at expanding the reach of precision therapeutics for serious inherited and acquired diseases.
Website60 First Street
Cambridge, MA, 02141
United States
The latest articles about PRME.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about PRME also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.